Announcement - Clontech Laboratories, Inc. Releases the Xfect™ Protein Transfection Reagent
MOUNTAIN VIEW, Calif., Dec. 1, 2010 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the upcoming (December 6th) release of its novel Xfect™ Protein Transfection Reagent. This new protein transfection reagent uses a cell-penetrating peptide developed at Clontech to bind and transport active proteins directly into a wide variety of mammalian cell types with little to no toxicity. Significantly, even hard-to-transfect human suspension cell lines and mouse embryonic stem cells can be efficiently transduced using this novel reagent.
Carol Lou, General Manager of Clontech Laboratories, Inc., comments: "We are pleased to announce the expansion of our Xfect Transfection Reagent product line to include this innovative Protein Transfection Reagent, as part of our commitment to enhancing and simplifying gene and protein delivery."
There is a growing demand for tools to deliver active proteins directly into cells for studies including transcriptional regulation, cell cycle, apoptosis, oncogenesis, epigenetics, and cell regeneration, e.g. iPS and trans-differentiation. Compared to traditional gene expression studies using transfected DNA, protein transfection is extremely rapid (1–2 hours compared to 12–24 hours) because it bypasses cellular processes such as transcription and translation. Protein transfection also facilitates studies involving transient effects of proteins, and avoids potentially harmful, random DNA integration into the genome of the target cells.
About Clontech Laboratories, Inc.
Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Clontech and Takara brands. Key products include high-performance qPCR and PCR reagents (including the Ex Taq™, LA Taq™, Titanium®, and Advantage® enzymes); RT enzymes and SMART™ library construction kits; the innovative In-Fusion® cloning system; Tet-based inducible gene expression systems; and a range of Macherey-Nagel nucleic acid purification tools. These and other products support applications including gene discovery, regulation, and function; protein expression and purification; RNAi and stem cell studies; and plant and food research. For more information, visit www.clontech.com.
About Takara Bio Inc.
Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is used as a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com.
SOURCE Clontech Laboratories, Inc.